Centre: 3 COVID-19 vaccine candidates in advanced stage of clinical trials

Updated: 19 September, 2020 12:46 IST | PTI | New Delhi

A high-level expert group is looking into matters related to vaccine distribution and immunisation

This picture has been used for representational purposes
This picture has been used for representational purposes

Three of the nearly 30 coronavirus vaccine candidates in the country are in advanced stages of clinical trials, while four are in pre-clinical development stage, Science and Technology Ministry Harsh Vardhan said on Friday.

A high-level expert group is looking into matters related to vaccine distribution and immunisation, he said.

"Nationally, nearly 30 vaccine candidates are under development, by both industry and academia. These vaccines are in different stages of pre-clinical and clinical development of which three candidates are in advanced stage of Phase I/II/III trials and four are in advanced pre-clinical development stage," Vardhan said in a written response to a question in the Lok Sabha.

The distribution and immunisation of the coronavirus vaccine are subject to availability, the minister said.

"Once available, the coronavirus vaccine distribution follows the same route as for the current practice of vaccines distribution under Universal Immunisation Program (UIP)," he added.

Vardhan said five National COVID-19 Biorepositories have been established by the Department of Biotechnology (DBT). This is a part of the network of 16 COVID-19 biorepositories established in the country by Department of Biotechnology, Indian Council of Medical Research and Council of Scientific and Industrial Research, he added.

So far, 44,452 clinical samples and 17 virus isolates have been collected which are accessible to researchers and industry for developing diagnostics, therapeutics and vaccines, the minister said.

Keep scrolling to read more news

Catch up on all the latest Crime, National, International and Hatke news here. Also download the new mid-day Android and iOS apps to get latest updates.

Mid-Day is now on Telegram. Click here to join our channel (@middayinfomedialtd) and stay updated with the latest news

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever

First Published: 19 September, 2020 12:04 IST

Sign up for all the latest news, top galleries and trending videos from Mid-day.com

Subscribe
loading image
This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK